Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)

被引：10

作者：

Perrot, Aurore ^{[1
]}

Lauwers-Cances, Valerie ^{[2
]}

Touzeau, Cyrille ^{[3
]}

Decaux, Olivier ^{[4
]}

Hulin, Cyrille ^{[5
]}

Macro, Magaret ^{[6
]}

Stoppa, Anne-Marie ^{[7
]}

Chretien, Marie Lorraine ^{[8
]}

Karlin, Lionel ^{[9
]}

Mariette, Clara ^{[10
]}

Jacquet, Caroline ^{[11
]}

Roussel, Murielle ^{[12
]}

Guillemot, Coralie ^{[13
]}

Devlamynck, Laure ^{[2
]}

Avet-Loiseau, Herve ^{[14
]}

Moreau, Philippe ^{[15
]}

Attal, Michel ^{[16
]}

机构：

[1] Ctr Hosp Univ Toulouse, Serv Hematol, Toulouse, France

[2] CHU Toulouse, serv Epidemiol, USMR, Toulouse, France

[3] CHU Nantes, Hematol, Ctr Rech Cancerol & Immunol Nantes Angers CRCINA, Nantes, France

[4] CHU Rennes, Serv Hematol, Rennes, France

[5] Hop Haut Leveque, Univ Hosp, Pessac, France

[6] Ctr Hosp Univ CHU Caen, Caen, France

[7] Inst Paoli Calmettes, Marseille, France

[8] CHU Dijon, Serv Hematol Clin, Dijon, France

[9] Univ Claude Bernard Lyon 1, CHU Lyon Sud, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[10] CHU Grenoble, Serv Hematol, Grenoble, France

[11] CHRU Nancy, Vandoeuvre Les Nancy, France

[12] CHU Limoges, Hematol, Limoges, France

[13] IUCT Oncopole, Pharm Unite Essais Clin, Toulouse, France

[14] UPS, CHU Toulouse, Unite Genom Myelome, IUCT Oncopole, Toulouse, France

[15] CHU Nantes, Nantes, France

[16] Inst Univ Canc Toulouse Oncopole, Toulouse, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

464

引用

页数：5

共 50 条

[31] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin
Voorhees, Peter M.
Rodriguez, Cesar
Reeves, Brandi
Nathwani, Nitya
Costa, Luciano J.
Lutska, Yana
Bobba, Padma
Hoehn, Daniela
Pei, Huiling
Ukropec, Jon
Qi, Ming
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2020, 136
[32] Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D.
Nathwani, Nitya
Shah, Nina D.
Efebera, Yvonne A.
Costello, Caitlin L.
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2019, 134
[33] Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study
Kumar, Shaji K.
Facon, Thierry
Usmani, Saad Z.
Plesner, Torben
Orlowski, Robert Z.
Touzeau, Cyrille
Basu, Supratik
Bahlis, Nizar J.
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Venner, Christopher P.
Weisel, Katja
Hulin, Cyrille
Karlin, Lionel
Preis, Meir
Broyl, Annemiek
Renwick, William
Hansson, Markus
Krevvata, Maria
Wang, Jianping
Van Rampelbergh, Rian
Ukropec, Jon
Uhlar, Clarissa M.
Kobos, Rachel
Perrot, Aurore
BLOOD, 2020, 136
[34] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS).
Sonneveld, Pieter
Broijl, Annemiek
Gay, Francesca
Boccadoro, Mario
Einsele, Hermann
Blade, Joan
Dimopoulos, Meletios A.
Delforge, Michel
Spencer, Andrew
Hajek, Roman
Schjesvold, Fredrik
Lonergan, Sarah
Smith, Elena
Carson, Robin L.
Crist, Wendy
Garvin, Wendy S.
Vermeulen, Jessica
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.
Rodriguez-Otero, Paula
Moreau, Philippe
Dimopoulos, Meletios Athanasios
Beksac, Meral
Perrot, Aurore
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
van de Donk, Niels W. C. J.
Schjesvold, Fredrik
Delforge, Michel
Einsele, Hermann
Spencer, Andrew
Lonergan, Sarah
Vieyra, Diego
Sitthi-Amorn, Anna
Carson, Robin L.
Blade, Joan
Boccadoro, Mario
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)
Dimopoulos, Meletios A.
Sonneveld, Pieter
Rodriguez-Otero, Paula
Quach, Hang
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
Nijhof, Inger S.
van de Donk, Niels W. C. J.
Katodritou, Eirini
Schjesvold, Fredrik
Balari, Anna Sureda
Rosinol, Laura
Delforge, Michel
Roeloffzen, Wilfried
Driessen, Christoph
Vangsted, Annette
Einsele, Hermann
Spencer, Andrew
Hajek, Roman
Jurczyszyn, Artur
Lonergan, Sarah
Liu, Yanfang
Wang, Jianping
Vieyra, Diego
van Brummelen, Emilie M. J.
Vanquickelberghe, Veronique
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Blade, Joan
Boccadoro, Mario
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S547 - S548
[37] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study
Kumar, S. K.
Moreau, P.
Bahlis, N.
Facon, T.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Raje, N.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Wang, G.
Krevvata, M.
Carson, R.
Borgsten, F.
Usmani, S. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 183 - 184
[38] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
Kumar, Shaji K.
Moreau, Philippe
Bahlis, Nizar Jacques
Facon, Thierry
Plesner, Torben
Orlowski, Robert Z.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Usmani, Saad
BLOOD, 2022, 140 : 10150 - 10153
[39] A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients
Silvennoinen, Raija
Waage, Anders
Peceliunas, Valdas
Schjesvold, Fredrik
Anttila, Pekka
Uttervall, Katarina
Saily, Marjaana
Putkonen, Mervi
Carlson, Kristina
Haukas, Einar
Sankelo, Marja
Partanen, Anu
Szatkowski, Damian
Hansson, Markus
Marttila, Anu
Svensson, Ronald
Axelsson, Per
Lauri, Birgitta
Mikkola, Maija
Karlsson, Conny
Abelsson, Johanna
Ahlstrand, Erik
Sikio, Anu
Nahi, Hareth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S157 - S157
[40] High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
Corre, Jill
Lambert, Jerome
Bobin, Arthur
Manier, Salomon
Perrot, Aurore
Karlin, Lionel
Roussel, Murielle
Bigot, Noemie
Benbrahim, Omar
Allangba, Olivier Thierry
Rey, Philippe
Dorvaux, Veronique
Vignon, Marguerite
Roland, Virginie
Garidi, Reda
Bastie, Jean-Noel
Chretien, Marie-Lorraine
Godet, Sophie
Montes, Lydia
Cherel, Brieuc
Chalopin, Thomas
Slama, Borhane
Laribi, Kamel
Dingremont, Claire
Roul, Christophe
Richez, Valentine
Mariette, Clara
Rigaudeau, Sophie
Calmettes, Claire
Dib, Mamoun
Tiab, Mourad
Vincent, Laure
Delaunay, Jacques
Marolleau, Jean Pierre
Godmer, Pascal
Frenzel, Laurent
Le Calloch, Ronan
Chalayer, Emilie
Gardeney, Helene
Macro, Margaret
Royer, Bruno
Decaux, Olivier
Arnulf, Bertrand
Merzoug, Karim Belhadj
Touzeau, Cyrille
Mohty, Mohamad
Gontier, Aurelie
Kasmi, Amine
Moreau, Philippe
Facon, Thierry
BLOOD, 2024, 144 : 4756 - 4758

← 1 2 3 4 5 →